A new chapter in the treatment of attention and mood has quietly opened at the American pharmacy counter, where centanafadine — sold as Simtriyo — becomes the first ADHD medication to engage dopamine, noradrenaline, and serotonin simultaneously. Approved by the FDA for adults and children six and older, it arrives not as a revolution but as an expansion of possibility, offering another path for those whose minds have not found peace with existing options. Its full place in the human story of psychiatric care remains unwritten, pending the slower work of real-world experience, comparative resea